Advertisement
INSM or PRAX or ZTS
Which Stock Would AI Choose? Insmed Incorporated (INSM) vs. Praxis Precision Medicines (PRAX) vs. Zoetis Inc. (ZTS) Stock Comparison
Key Takeaways
- INSM delivered strong 2025 revenue growth of 67% to $606M, driven by ARIKAYCE and BRINSUPRI launches, with 2026 guidance signaling at least $1B from BRINSUPRI alone.
- PRAX shares surged over 680% in the past year amid NDA filings for ulixacaltamide and relutrigine, both with FDA Breakthrough Therapy Designation, positioning it for potential CNS disorder approvals.
- ZTS, the largest by market cap at $51B, faces recent share weakness near 52-week lows due to companion animal pressures and competition, despite acquisitions like Neogen genomics.
- Biotech peers INSM and PRAX show higher momentum and analyst upside (targets ~$200+ and $600+), contrasting ZTS's stability but muted growth outlook.
- Relative performance highlights biotech volatility versus ZTS's defensive animal health exposure, with sector sentiment favoring catalysts in rare diseases.
- Tickeron's AI bots, including a biotech-focused one with 95% win rate, underscore tools for navigating such stock comparisons in volatile markets.
Introduction
This stock comparison examines INSM, PRAX, and ZTS, three healthcare firms spanning biopharma innovation and animal health. INSM and PRAX target rare respiratory and CNS disorders with recent commercial and regulatory milestones, while ZTS leads in veterinary products amid sector headwinds. Traders seeking momentum from catalysts like NDAs and revenue beats, or investors prioritizing established revenue streams, will find value in analyzing their relative performance, valuations, and market positioning in today's dynamic healthcare landscape.
INSM Overview and Recent Performance
Insmed Incorporated (INSM) is a global biopharmaceutical company developing therapies for serious rare diseases, primarily respiratory conditions. Its approved product ARIKAYCE treats refractory nontuberculous mycobacterial lung disease, while BRINSUPRI (brensocatib), a DPP1 inhibitor, targets bronchiectasis following recent approvals.
In recent market activity, INSM shares traded around $139, up 88% over the past year and 20% YTD, reflecting robust revenue execution. Full-year 2025 total revenues hit $606M, a 67% increase, with ARIKAYCE at $434M (19% growth, exceeding guidance) and BRINSUPRI launching to $173M. The company guided 2026 ARIKAYCE to $450-470M and BRINSUPRI to at least $1B, fueling optimism. Analyst upgrades, like BofA's $211 target, have supported sentiment amid pipeline readouts for pulmonary hypertension and other indications.
PRAX Overview and Recent Performance
Praxis Precision Medicines, Inc. (PRAX) is a clinical-stage biopharma leveraging genetic insights for CNS disorders via neuronal excitation-inhibition imbalance. Its Cerebrum platform yields small molecules like ulixacaltamide (essential tremor) and relutrigine (SCN2A/SCN8A developmental epileptic encephalopathies), with Solidus for antisense therapies.
Recent weeks saw PRAX shares near $303, posting a staggering 687% one-year gain and 3% YTD amid high volatility (52-week range $27-$356). Momentum stems from NDA submissions for ulixacaltamide and relutrigine, both earning FDA Breakthrough Therapy Designation after positive Phase 3 data in essential tremor and DEEs. Pre-NDA FDA alignments and a cash runway into 2028 bolster confidence, with analysts like Wolfe initiating Outperform at $500. Strong investor interest reflects potential first-in-class approvals in underserved neurology markets.
ZTS Overview and Recent Performance
Zoetis Inc. (ZTS) dominates animal health, offering medicines, vaccines, diagnostics, and precision tools for companion and livestock species worldwide. Key franchises include parasiticides, dermatology, and anti-infectives, with growth in biodevices and genomics.
In recent trading, ZTS hovered at $115, down to 52-week lows (range $115-$172), with 28% one-year and 8% YTD declines amid broader pressures. Q4 2025 revenue rose 3% to $2.4B, full-year $9.5B (6% organic), but companion animal softness and Librela competition tempered guidance to 3-5% 2026 growth ($9.8-10B revenue). The $160M Neogen genomics acquisition aims to bolster livestock precision health, though shares slipped on integration concerns. Analysts maintain moderate targets around $151.
Trending AI Robots
Tickeron’s Trending AI Robots page features a curated selection of top-performing AI trading bots from its library of hundreds, which scan thousands of tickers for real-time signals across strategies like trend following, dip buying, and sector momentum. Only bots excelling in current volatility—such as a biotech ETF agent with 95% win rate, 24% annualized return, and 3-day trades—earn trending status, alongside others boasting 50-95% win rates, profit factors up to 9x, and returns from 17% to 216%. Timeframes span 5min scalps to 60-day holds, covering stocks, ETFs, and crypto in sectors like biotech, semis, and energy. These diverse AI agents help traders adapt to market shifts; explore the full lineup at Trending AI Robots for data-driven edges.
Head-to-Head Comparison
INSM and PRAX emphasize high-risk biotech models reliant on rare disease catalysts—INSM via commercial ramps (BRINSUPRI/ARIKAYCE), PRAX on NDAs—yielding explosive momentum (88% and 687% 1-year gains) but volatility versus ZTS's $9.5B revenue stability. Growth drivers diverge: biotechs eye $1B+ peaks and approvals, while ZTS leverages livestock genomics amid companion slowdowns (3-5% organic growth).
Risk profiles contrast sharply—INSM/PRAX face regulatory/pipeline hurdles, ZTS macro pet spending and competition. Sector exposure pits human rare diseases against animal health, with biotechs more sensitive to trial data. Valuations reflect: ZTS trades at a premium on earnings (P/E ~19), biotechs on forward potential (analyst targets imply 40-100% upside). Sentiment favors biotech catalysts over ZTS's recent downgrades.
Tickeron AI Verdict
Tickeron’s AI currently leans toward PRAX for its superior trend consistency via NDA momentum and 687% trailing returns, outpacing INSM's revenue beats and ZTS's stability amid declines. With biotech bots signaling high win rates in the sector, PRAX's catalysts offer probabilistic edge in relative performance, though biotechs carry execution risks versus ZTS's lower volatility.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INSM’s FA Score shows that 0 FA rating(s) are green whilePRAX’s FA Score has 0 green FA rating(s), and ZTS’s FA Score reflects 2 green FA rating(s).
- INSM’s FA Score: 0 green, 5 red.
- PRAX’s FA Score: 0 green, 5 red.
- ZTS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INSM’s TA Score shows that 3 TA indicator(s) are bullish while PRAX’s TA Score has 5 bullish TA indicator(s), and ZTS’s TA Score reflects 4 bullish TA indicator(s).
- INSM’s TA Score: 3 bullish, 6 bearish.
- PRAX’s TA Score: 5 bullish, 4 bearish.
- ZTS’s TA Score: 4 bullish, 4 bearish.
Price Growth
INSM (@Biotechnology) experienced а -6.64% price change this week, while PRAX (@Biotechnology) price change was +8.34% , and ZTS (@Pharmaceuticals: Generic) price fluctuated +3.84% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.61%. For the same industry, the average monthly price growth was +9.02%, and the average quarterly price growth was +11.47%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.70%. For the same industry, the average monthly price growth was +8.17%, and the average quarterly price growth was +2.15%.
Reported Earning Dates
INSM is expected to report earnings on Apr 30, 2026.
PRAX is expected to report earnings on May 13, 2026.
ZTS is expected to report earnings on May 07, 2026.
Industries' Descriptions
@Biotechnology (+7.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Generic (+3.70% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| INSM | PRAX | ZTS | |
| Capitalization | 31.2B | 9.54B | 51.5B |
| EBITDA | -1.18B | -326.06M | 4.07B |
| Gain YTD | -16.956 | 16.204 | -2.319 |
| P/E Ratio | N/A | N/A | 20.33 |
| Revenue | 606M | 0 | 9.47B |
| Total Cash | 1.43B | 599M | 2.31B |
| Total Debt | 587M | 110K | 9.24B |
INSM | ZTS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 62 | 7 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 76 Overvalued | 30 Undervalued | |
PROFIT vs RISK RATING 1..100 | 37 | 100 | |
SMR RATING 1..100 | 100 | 16 | |
PRICE GROWTH RATING 1..100 | 49 | 62 | |
P/E GROWTH RATING 1..100 | 100 | 85 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ZTS's Valuation (30) in the Pharmaceuticals Generic industry is somewhat better than the same rating for INSM (76) in the Biotechnology industry. This means that ZTS’s stock grew somewhat faster than INSM’s over the last 12 months.
INSM's Profit vs Risk Rating (37) in the Biotechnology industry is somewhat better than the same rating for ZTS (100) in the Pharmaceuticals Generic industry. This means that INSM’s stock grew somewhat faster than ZTS’s over the last 12 months.
ZTS's SMR Rating (16) in the Pharmaceuticals Generic industry is significantly better than the same rating for INSM (100) in the Biotechnology industry. This means that ZTS’s stock grew significantly faster than INSM’s over the last 12 months.
INSM's Price Growth Rating (49) in the Biotechnology industry is in the same range as ZTS (62) in the Pharmaceuticals Generic industry. This means that INSM’s stock grew similarly to ZTS’s over the last 12 months.
ZTS's P/E Growth Rating (85) in the Pharmaceuticals Generic industry is in the same range as INSM (100) in the Biotechnology industry. This means that ZTS’s stock grew similarly to INSM’s over the last 12 months.
| INSM | PRAX | ZTS | |
|---|---|---|---|
| RSI ODDS (%) | N/A | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 78% | 2 days ago 90% | 2 days ago 62% |
| Momentum ODDS (%) | 2 days ago 74% | 2 days ago 90% | 2 days ago 61% |
| MACD ODDS (%) | 2 days ago 66% | 2 days ago 90% | 2 days ago 65% |
| TrendWeek ODDS (%) | 2 days ago 72% | 2 days ago 86% | 2 days ago 56% |
| TrendMonth ODDS (%) | 2 days ago 74% | 2 days ago 88% | 2 days ago 54% |
| Advances ODDS (%) | 18 days ago 71% | 5 days ago 84% | 5 days ago 52% |
| Declines ODDS (%) | 3 days ago 73% | 3 days ago 84% | 3 days ago 58% |
| BollingerBands ODDS (%) | 2 days ago 70% | 2 days ago 86% | 2 days ago 62% |
| Aroon ODDS (%) | 2 days ago 84% | 2 days ago 86% | 2 days ago 61% |
Advertisement
PRAX and
Correlation & Price change
A.I.dvisor indicates that over the last year, PRAX has been loosely correlated with BEAM. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if PRAX jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To PRAX | 1D Price Change % | ||
|---|---|---|---|---|
| PRAX | 100% | +6.90% | ||
| BEAM - PRAX | 40% Loosely correlated | +3.49% | ||
| BHVN - PRAX | 37% Loosely correlated | +9.69% | ||
| RAPP - PRAX | 35% Loosely correlated | +0.58% | ||
| VERU - PRAX | 35% Loosely correlated | -1.21% | ||
| RXRX - PRAX | 35% Loosely correlated | +5.00% | ||
More | ||||
ZTS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with ELAN. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then ELAN could also see price increases.
| Ticker / NAME | Correlation To ZTS | 1D Price Change % | ||
|---|---|---|---|---|
| ZTS | 100% | +2.81% | ||
| ELAN - ZTS | 52% Loosely correlated | +2.38% | ||
| PRGO - ZTS | 38% Loosely correlated | +3.33% | ||
| VTRS - ZTS | 37% Loosely correlated | +4.78% | ||
| HLN - ZTS | 37% Loosely correlated | +1.67% | ||
| PAHC - ZTS | 36% Loosely correlated | +5.92% | ||
More | ||||